New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:31 EDTISISIsis Pharmaceuticals reports final Phase 2 data on ISIS-APOCIII Rx
Isis Pharmaceuticals announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIIIRx achieved average reductions of up to 71% in apolipoprotein C-III and up to 64% in triglycerides, and average increases of up to 52% in high-density lipoprotein cholesterol, the 'good' cholesterol. While the starting average triglyceride level in the 300 mg group was 384 mg/dL, 70% of these patients reduced their triglyceride level to below the normal level of 150 mg/dL. In addition, lipoprotein particle analysis showed significant dose-dependent reductions in the number of very low-density lipoprotein particles and significant increases in the number of HDL particles.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
10:00 EDTISISOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:22 EDTISISIsis Pharmaceuticals downgraded at Stifel
Subscribe for More Information
08:06 EDTISISIsis Pharmaceuticals downgraded to Hold from Buy at Stifel
Subscribe for More Information
07:04 EDTISISIsis Pharmaceuticals earns $15M from GlaxoSmithKline for advancing ISIS-TTR Rx
Isis Pharmaceuticals (ISIS) announced that it has earned a $15M milestone payment from GSK (GSK) related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug Isis is developing with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $60 million in upfront and milestone payments for advancing ISIS-TTRRx. In addition, if GSK elects to exercise its option to exclusively license ISIS-TTRRx, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
February 27, 2015
09:43 EDTISISIsis Pharmaceuticals sees reporting data on eight or more drugs in FY15
Sees initiating up to 13 studies, broadening pipeline with up to five new drugs in partnered, unpartnered programs.
09:38 EDTISISIsis Pharmaceuticals sees FY15 pro forma NOL in mid-$50M range
Sees ending FY15 with more than $630M in cash, representing net cash outflows of only $100M to move forward its pipeline.
09:34 EDTISISIsis Pharmaceuticals reports Q4 EPS 25c, consensus 2c
Subscribe for More Information
February 26, 2015
15:30 EDTISISNotable companies reporting before tomorrow's open
Subscribe for More Information
February 24, 2015
10:48 EDTISISIsis says ISIS-PKKRx reduced prekallikrein levels in Phase 1 study
Isis Pharmaceuticals announced results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95% in prekallikrein, or PKK, Isis said. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema. ISIS-PKKRx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg up to 400 mg for the multiple doses. After three weeks of dosing, subjects in the 100, 200, 300 and 400 mg multiple-dose cohorts displayed a mean reduction of PKK of 33, 69, 87 and 92%, respectively, from baseline. In this study, ISIS-PKKRx was generally well tolerated.
February 23, 2015
07:22 EDTISISSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 20, 2015
15:20 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use